

LIEGE, Belgium, January 8, 2014 /PRNewswire/ --

Drug-Free Migraine Treatment CEFALY®: Publication of a Study Conducted on 2,313 Patients.

The scientific journal "JOURNAL of HEADACHE and PAIN" publishes positive results from a clinical study conducted on 2,313 patients which confirms the high efficacy and safety of the medical device CEFALY ® migraine treatment.

<http://www.thejournalofheadacheandpain.com/content/14/1/95>

The efficacy and safety of the CEFALY ® medical device for migraine treatment had already been reported early 2013 in the scientific journal "Neurology" (Official Journal of the American Academy of Neurology). Today published data on a large number of individuals confirm significant improvement for the majority of patients. Following 2 months of treatment, 54.4% of the patients described a very significant improvement and decided to purchase the device. If we rule out those patients who hadn't used the device, or who had only used it to a negligible degree, and observe only regular users, the percentage of patients with a very significant improvement is 81%. Side effects are reported by only 4.3% of patients, all of which are minor and completely reversible. Therefore the effectiveness/safety ratio is excellent.

Current anti-migraine medications are only moderately effective and often not well tolerated. In addition, overuse of anti-migraine medications is an essential factor in the worsening of the disease and its development into chronic migraine. Cefaly ® is therefore a means of choice to treat a majority of migraine patients.

Cefaly® is an innovative medical device protected by a number of patents. It is the first device to offer external cranial neurostimulation. Cranial neurostimulation is a technique that has been used for a number of years in neurology, but this has been carried out using implantable neurostimulators (similar to a pacemaker). The technological advances made by Cefaly means that there is now a simple, lightweight, economical and comfortable device available that offers migraine patients a method of treatment that is neither drug-based nor invasive.

A self-adhesive electrode is placed on the forehead and the device is positioned on this electrode, worn like a pair of glasses. Highly precise impulses are transmitted through the electrode to the nerve endings of the upper branch of the trigeminal nerve.

The Cefaly® medical device is available on the European market and in Canada; FDA approval for USA is expected in the coming months.

<http://www.cefaly.com>

CEFALY Technology

ZI des Hauts Sarts

4eme Avenue N 5
B-4040, Herstal, Liege
Belgium

Phone: +3243676722;

Fax: +3243676702;

info@cefaly.com.

Press Contact:

Aurelie SERVAES,

Mobile: +32473487166,

a.servaes@cefaly.com